Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
TGCT is a rare disease that is difficult to manage, surgical resection is the primary
 treatment currently available. To date no disease registry exists and there is little data
 available detailing the management of patients with diffuse TGCT, the burden of diffuse TGCT
 for patients (including pain, joint stiffness, swelling, reduced mobility and quality of
 life) or the economic impact of diffuse TGCT.

 This study aims to collect data by an observational disease registry involving no
 intervention to the patient or changes to investigators treatment decisions.
GCT is a rare, benign, but potentially locally aggressive and recurrent disease. Treatment
 pattern and treatment initiation, continuation or changes are solely at the discretion of the
 physician and the patient.

 There will be no attempt to influence the prescribing patterns of any individual treating
 physician. All medication will be prescribed in the usual standard of care and will not be
 provided by the study sponsor.

 Participation in the study will in no way influence payment or reimbursement for any
 treatment received by patients during the study.

 It is the responsibility of the investigator and his study staff to enter all relevant
 patient data required for this registry in the electronic Case Report Form (eCRF) and in the
 patients' medical records.

 Approximately 15 sites from up to 6 European Countries (France, Germany, Italy, The
 Netherlands, Spain and United Kingdom) and 4 sites from the US are planned to participate.
 The sites will be specialized sites that treat diffuse TGCT regularly.
Inclusion Criteria:

 -  Written informed consent for participation in the study (ICF)

 -  Patients with diffuse TGCT (diagnosed histologically) confirmed naïve or recurrent
 case

 Exclusion Criteria:

 -  None